Clinical Trials Logo
  1. Home
  2. ANCA-associated Vasculitis
  3. NCT05197842

Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

ANCA-associated Vasculitis Clinical Trial

Official title:
A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase I/II Trial to Study Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With ANCA-associated Vasculitis

Clinical Trial Summary

The aim of the trial is to study the efficacy and safety of treatment with BDB-001 Injection substitution of glucocorticoid in patients with ANCA-associated vasculitis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05197842
Study type Interventional
Source Staidson (Beijing) Biopharmaceuticals Co., Ltd
Contact Zheng Xiaohong
Phone +86 13811686425
Email zhengxiaohong@staidson.com
Status Recruiting
Phase Phase 1/Phase 2
Start date February 22, 2022
Completion date March 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02257866 - Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Completed NCT02463539 - Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis N/A
Recruiting NCT05897684 - Avacostar - (PASS)
Recruiting NCT05364892 - Biocollection of Patients With ANCA Associated Vasculitis N/A
Terminated NCT00482066 - Abatacept in ANCA Associated Vasculitis Phase 2
Not yet recruiting NCT02126098 - Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis N/A
Recruiting NCT05965284 - Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM) Phase 4
Recruiting NCT06285279 - FKC288 in Participants With Autoimmune Kidney Diseases Phase 1
Completed NCT02994927 - A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Phase 3
Recruiting NCT02463578 - Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis N/A
Active, not recruiting NCT05716334 - Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
Recruiting NCT05383573 - Pediatric ANCA Associated-vasculitis
Completed NCT02222155 - Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis Phase 2
Completed NCT02954705 - MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS
Completed NCT04280601 - PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis N/A
Active, not recruiting NCT02108860 - Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) Phase 3